Combined venetoclax and hypomethylating agent (HMA) therapy induces high response rates in patients with myelodysplastic syndrome including patients previously failing HMA Meeting Abstract
| Authors: | Ball, B. J.; Famulare, C.; Stein, E. M.; Tallman, M. S.; Gill, S. I.; Manning, B. M.; Koprivnikar, J.; McCloskey, J.; Testi, R.; Al Ali, N.; Sallman, D. A.; Padron, E.; Goldberg, A. D.; Komrokji, R. S. |
| Abstract Title: | Combined venetoclax and hypomethylating agent (HMA) therapy induces high response rates in patients with myelodysplastic syndrome including patients previously failing HMA |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164602264 |
| DOI: | 10.1182/blood-2019-125113 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4241 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work